Oral News and Research

RSS

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others. The move opens the way to improve access to innovative medicines that show clear clinical benefits and could have enormous public health impact globally.

8 May 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.

8 May 2015

Removing bacterial biofilms could help prevent and treat colon cancers, study suggests

A team led by scientists at The Scripps Research Institute and Johns Hopkins University School of Medicine has uncovered a big clue to how bacteria may promote some colon cancers.

8 May 2015

Natural substance could help people avoid cavities, gum disease

Arginine, a common amino acid found naturally in foods, breaks down dental plaque, which could help millions of people avoid cavities and gum disease, researchers at the University of Michigan and Newcastle University have discovered.

8 May 2015

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

The World Health Organization (WHO) today published the new edition of its Model List of Essential Medicines) which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others...

8 May 2015

SLU professor reveals why women have higher rates of strokes than men, suggests steps to reduce risk

Each year, around 55,000 more women than men will have a stroke. Longer lifespans, pregnancies and hormones all contribute to the disparity, as do illnesses that tend to strike women more frequently. Crunch the numbers and the math adds up to more strokes for women, making it important for women monitor their risk.

8 May 2015

Egalet announces business highlights, financial results for first quarter 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today reported business highlights and financial results for the three months ended March 31, 2015.

7 May 2015

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

MSI Methylation Sciences, Inc., a pharmaceutical company developing a once-daily oral, small molecule therapy for adjunctive treatment of major depressive disorder (MDD), announced the completion of patient recruitment for its HORIZON Phase 2 Study.

7 May 2015

Penn study highlights need for more guidance on contraceptive use in women with cystic fibrosis

Only half of women with cystic fibrosis (CF) report using contraception and frequently apt to become pregnant unintentionally, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania.

7 May 2015

Treatment significantly reduces risk of CDI recurrence

Among patients with Clostridium difficile infection (CDI) who recovered following standard treatment with the antibiotics metronidazole or vancomycin, oral administration of spores of a strain of C difficile that does not produce toxins colonized the gastrointestinal tract and significantly reduced CDI recurrence, according to a study in the May 5 issue of JAMA.

7 May 2015

Fecal transplantation cures C. diff infection, eliminates multi-drug resistant pathogens

A fecal microbiota transplant (FMT) not only cured a case of Clostridium difficile (C. diff) infection in a 66 year old man; it eliminated populations of multi-drug resistant organisms both in the patient's gastrointestinal tract, and several other body sites.

7 May 2015

Winners of PDA's 2015 National Children's Dental Health Month statewide poster contest announced

Third-grader Davida Brannigan of Solomon Plains Elementary in Luzerne County will receive a $500 prize for winning first place in the Pennsylvania Dental Association's 2015 National Children's Dental Health Month (NCDHM) statewide poster contest.

6 May 2015

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

Symbiomix Therapeutics today announced multiple milestones, including the closing of the third and final tranche of a $41 million Series A financing and positive results from a multi-center, randomized Phase 2 trial testing a single oral dose of SYM-1219 for the treatment of bacterial vaginosis (BV).

6 May 2015

Mylan releases generic version of Seasonale Tablets in the U.S.

Mylan N.V. today announced the U.S. launch of Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg, which is the generic version of Teva's Seasonale Tablets. Mylan's partner Famy Care Ltd. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

5 May 2015

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period.

5 May 2015

Caregiver's behavior influences oral health habits in children

Studies have long associated low-income areas with poor oral health. But dental researchers at Case Western Reserve University and University of Washington sensed that other factors related to income may be at work -- in particular, education level.

5 May 2015

Green tea compound, voluntary exercise slow Alzheimer's disease progression in mice

According to the National Institutes of Health, Alzheimer's disease (AD) may affect as many as 5.5 million Americans. Scientists currently are seeking treatments and therapies found in common foods that will help stave off the disease or prevent it completely.

5 May 2015

IQWiG finds minor added benefit of dulaglutide in combination with short-acting insulin for type 2 diabetes

Since 2014 dulaglutide has been approved alone or in combination with other drugs for the treatment of adults with type 2 diabetes. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapies.

5 May 2015

Pre-POINT trial raises hope for Type 1 diabetes prevention

Giving oral insulin to children at genetic high risk of diabetes stimulates a regulatory immune response without inducing hypoglycaemia, show the findings of the Pre-POINT study.

1 May 2015

Research provides insights into the ability of FL118 to overcome treatment resistance

The latest research from the team that discovered the novel anticancer agent FL118 highlights distinctive characteristics of this small-molecule compound and provides insights into its ability to overcome the persistent problem of treatment resistance. In findings reported in Molecular Cancer, Fengzhi Li, PhD, of Roswell Park Cancer Institute, and colleagues provide new evidence that FL118 may be more effective than two structurally similar injectable drugs and, additionally, may be effective as an oral agent.

30 Apr 2015

Oral News and Research

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Removing bacterial biofilms could help prevent and treat colon cancers, study suggests

Natural substance could help people avoid cavities, gum disease

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

SLU professor reveals why women have higher rates of strokes than men, suggests steps to reduce risk

Egalet announces business highlights, financial results for first quarter 2015

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

Penn study highlights need for more guidance on contraceptive use in women with cystic fibrosis

Treatment significantly reduces risk of CDI recurrence

Fecal transplantation cures C. diff infection, eliminates multi-drug resistant pathogens

Winners of PDA's 2015 National Children's Dental Health Month statewide poster contest announced

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

Mylan releases generic version of Seasonale Tablets in the U.S.

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

Caregiver's behavior influences oral health habits in children

Green tea compound, voluntary exercise slow Alzheimer's disease progression in mice

IQWiG finds minor added benefit of dulaglutide in combination with short-acting insulin for type 2 diabetes

Pre-POINT trial raises hope for Type 1 diabetes prevention

Research provides insights into the ability of FL118 to overcome treatment resistance

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News